KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.

Peter Nordbeck, Ozlem Goker-Alpan, John A Bernat, Dominique P Germain, Pilar Giraldo, Ana Jovanovic, Virginia Kimonis, Kathleen Nicholls, Cheryl Rockman-Greenberg, Raphael Schiffmann, Mark Thomas, Anna Tylki-Szymanska, Eric Wallace, Richard W D Welford, Michael L West, Martine Clozel, Aline Frey, Luba Trokan, Markus S Mueller, Markus Vogler, Christoph Wanner, Derralynn Hughes

Nat Commun 17(1) 1534

PMID41519901
PMCIDPMC12891692
DOI10.1038/s41467-025-68256-5
发表日期2026-01-10
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other;Fig. 4:森林图/亚组分析图;Fig. 5:AI 判定为 other。
摘要

摘要

In Fabry disease (FD, OMIM #301500), a rare lysosomal storage disorder, the glucosylceramide synthase inhibitor lucerastat acts as substrate reduction therapy. The Phase 3, prospective, double-blind, placebo-controlled, 6-month, randomized clinical trial, MODIFY (NCT03425539), aimed to evaluate the efficacy, safety, and tolerability of lucerastat in adults with FD with moderate-to-severe neuropathic pain. The single-arm, open-label extension (OLE) (NCT03737214) evaluated the longer-term safety and tolerability of lucerastat over 72 months. Lucerastat 1000 mg twice daily (n = 80), compared with placebo (n = 37), failed to affect neuropathic pain at Month-6, with no significant difference between treatment groups (LSM difference -0.42 [95% CI -1.23, 0.40], p = 0.32) (primary endpoint). In contrast, a decrease in baseline plasma Gb3 was observed at Month-6 in lucerastat-treated participants but not placebo-treated participants (LSM difference -873.53 ng/mL [95% CI -1097.53, -649.53], p < 0.0001; NS due to hierarchical testing). In an unplanned OLE Month-18 interim analysis, the eGFR slope (mL/min/1.73m2/year) in 93 participants with pre- and post-randomization (23-month median lucerastat exposure) eGFR data was -3.50 (-5.04, -1.969) and -1.48 (-2.64, -0.33), respectively. Lucerastat was safe and well tolerated. Lucerastat's strong pharmacodynamic effect did not translate into an effect on neuropathic pain. The potential effect of lucerastat on renal function requires further investigation (Trial registration NCT03425539, NCT03737214; 2017-003369-85, 2018-002210-12. The studies were sponsored by Idorsia Pharmaceuticals Ltd).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. CONSORT diagram. AE adverse event, OLE open-label extension. *One participant was randomized but not treated. Source data are provided in the figure.
非 KM Figure
Fig. 2Fig. 2. Change over time in MODIFY of neuropathic pain, plasma Gb3 and gastrointestinal symptoms. Change from baseline over time in MODIFY in A neuropathic pain monthly score, B plasma Gb3, C abdominal pain monthly score, and D number of days with diarrhea. Gb3 globotriaosylceramide. The red dotted line represents participants receiving placebo during MODIFY; the solid blue line represents participants receiving lucerastat during MODIFY. The graphs ( A – D ) include all participants who received at least one dose of study treatment and (for graphs C and D ) experienced moderate-to-severe abdominal pain or diarrhea during the 4 weeks prior to randomization. Data are shown as least squares mean (95% CI) change from baseline ( A , C , D ) or mean (± SE) change from baseline ( B ). Source data are provided as a Source Data file.
非 KM Figure
Fig. 3Fig. 3. Change over time in MODIFY/OLE of plasma Gb3 and lysoGb3 and urine Gb3. Change from baseline over time in MODIFY and its OLE in A plasma Gb3, B plasma lysoGb3, and C urine Gb3. Gb3 globotriaosylceramide, lysoGb3 globotriaosylsphingosine, OLE open-label extension. The red dotted line represents participants receiving placebo during MODIFY; the solid blue line represents participants receiving lucerastat during MODIFY and the OLE; the dotted blue line represents participants receiving lucerastat in the OLE. Data are shown as mean (± SE) change from baseline. Source data are provided as a Source Data file.
非 KM Figure
Fig. 4Fig. 4. eGFR slopes in MODIFY/OLE participants in the overall population and subgroups: pre-randomization versus on lucerastat. ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, CI confidence interval, eGFR estimated glomerular filtration rate, ERT enzyme replacement therapy, LS least squares. Baseline is the last non-missing value recorded up to and including the MODIFY randomization visit (for participants randomized to lucerastat in MODIFY) or the OLE enrolment visit (for participants randomized to placebo in MODIFY). Data are presented overall and by subgroup comparing lucerastat to historical data from the same participants. The estimation of the covariance matrix was primarily based on “unstructured” covariance structure. In case the mixed model did not converge, it was replaced by the “variance components” structure, followed by the “compound symmetry” structure. Data are shown as least squares mean (95% CI) change from baseline. Source data are provided in the figure.
非 KM Figure
Fig. 5Fig. 5. Scatter plot of individual pre-randomization (x-axis) and lucerastat (y-axis) annualized eGFR slopes in MODIFY/OLE in participants with renal impairment. eGFR estimated glomerular filtration rate. Renal impairment is defined as baseline eGFR < 90 mL/min/1.73 m 2 . The pre-randomization eGFR slope was calculated from serum creatinine measured within 2 years prior to randomization in MODIFY, available for 93 participants. The colors indicate the categories of stable (green; annualized eGFR slope >−3 mL/min/1.73 m 2 ), deteriorating (yellow; ≥−5 and ≤−3 mL/min/1.73 m 2 ), or fast deteriorating (pink/red; <−5 mL/min/1.73 m 2 ). Source data are provided as a Source Data file.
非 KM Figure